Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Microbot Medical secured its first Office-Based Laboratory (OBL) customer, ELMNT IR, which signed an order for up to a 12-month supply of the LIBERTY Endovascular Robotic System. This marks the company's first customer on the U.S. West Coast and supports its strategy to expand into outpatient interventional radiology settings.
Esquire Financial Holdings reported Q3 2026 net income of $17.5 million, or $1.57 per diluted share, which included the impact of its transformational acquisition of Signature Bancorporation completed on August 1, 2026. On an adjusted basis excluding merger expenses, net income was $23.6 million with an industry-leading adjusted return on average tangible equity of 23.10%.
“This transformational merger enhances our operating profile, expands our resources, and diversifies our balance sheet, bringing together two institutions with highly complementary commercial banking operations and capabilities for continued expansion nationally.”
Andrew C. Sagliocca, Vice Chairman, CEO & President
“Most importantly, the merger unites two highly talented management teams with strong client relationships and market expertise, positioning the combined company for continued industry-leading growth, performance metrics and enhanced success.”
Andrew C. Sagliocca, Vice Chairman, CEO & President
Artiva Biotherapeutics is halting all development of its lead cell therapy candidate AlloNK (AB-101) and implementing a 94% workforce reduction after clinical data failed to meet durability thresholds and two patient deaths occurred. The company has engaged Leerink Partners to explore strategic alternatives, including a potential merger, sale, or liquidation, while reporting a preliminary cash balance of $319.1 million.
GrabAGun Digital Holdings Signs $34M M&A Deal with Camfour Holding, Inc.
GrabAGun Digital Holdings Inc. completed the acquisition of Camfour LLC, a national wholesale distributor of firearms and ammunition, for approximately $34.0 million in cash. The deal integrates Camfour's distribution infrastructure with GrabAGun's AI-driven technology platform to expand its reach into wholesale distribution and improve inventory productivity.
Peoples Bancorp EVP, Operations Mark Augenstein Sells $75.8K of Stock
Mark Augenstein, EVP, Operations, sold 2,000 shares of Peoples Bancorp Inc at $37.88 a share, worth $75.8K in total on Oct 23, 2026. Shares held after the trade: 24,885 (-7.4%).
Altimmune appointed Peter Greenleaf and Alex Howarth to its Board of Directors effective November 2, 2026, increasing the board size to eleven. As part of a planned transition, directors John M. Gill, Mitchel Sayare, and Klaus O. Schafer will retire at the 2027 Annual Meeting. The new directors will receive an annual cash retainer of $40,000 and initial stock options for 160,000 shares each.
Euronet Worldwide reported third quarter 2026 revenue of $1.16 billion, a 1% increase year-over-year, though net income fell to $113.6 million. The company noted persistent pressure in its Cross-Border Payments segment due to U.S. immigration policy and global economic factors, leading it to lower its full-year 2026 outlook. Despite these challenges, the company repurchased $50 million of common stock and saw 33% year-to-date growth in its digital accelerator initiatives.
Term
Q3 2026
“Our third-quarter results reflect the continued impact of U.S. immigration policy and global economic pressures on the Cross Border Payments segment, which has persisted longer than we anticipated. While these results are below our expectations and our historical performance, we continued to see growth in the digital accelerators we introduced during our Investor Day in May.”
Michael J. Brown, Chairman and Chief Executive Officer of Euronet Worldwide
CDT Equity entered into an evaluation agreement with Manoira Corporation to analyze clinical-stage compounds AZD1656 and AZD5904 for potential use in animal health products. As part of the arrangement and other corporate obligations, the company issued shares to Manoira to settle a $195,000 payment, as well as shares to a service provider and former CEO Dr. Andrew Regan for severance.
Millrose Properties reported record Q3 2026 net income of $130 million and total revenues of $211 million, driven by its homesite option platform. The company raised its Q4 AFFO guidance and the Board authorized a new $250 million share repurchase program. Subsequent to the quarter, the company completed $1.1 billion in capital support for Dream Finders Homes' acquisition of Beazer Homes.
Term
Q3 2026
“Millrose delivered a record third quarter, driven by disciplined underwriting and the resilience and adaptability of our platform in a challenging housing market. We have raised our outlook for the remainder of the year and authorized our first share repurchase program, reflecting our confidence in the durability of our cash flows and our commitment to disciplined capital allocation.”
Darren Richman, Chief Executive Officer and President
Bread Financial Holdings launched an underwritten public offering of depositary shares, each representing a 1/40th interest in its Series C Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock. The company intends to use the net proceeds for general corporate purposes, including potential capital contributions to its subsidiary, Comenity Capital Bank, and share repurchases.
Freeport-McMoRan reported Q3 2026 net income of $1.2 billion ($0.81 per share) on copper production of 832 million pounds. The company highlighted steady progress at the Grasberg minerals district and the re-commencement of smelter operations at PTFI, while continuing to advance organic copper growth projects in the Americas.
Term
Q3 2026
“The Freeport team delivered strong financial results in the third quarter and achieved several important milestones to drive value and support future growth. We made continued steady progress with the ramp-up of our large-scale underground operations in Indonesia and are advancing several organic growth opportunities in the Americas.”
Kathleen Quirk, President and Chief Executive Officer
Rallybio Corp has announced a proposed merger with Avenzo Therapeutics and continues to report significant losses as a pre-revenue clinical-stage biotechnology company. The company is heavily dependent on the development of its lead candidate, RLYB116, and expects to require substantial additional capital to fund future operations and clinical trials.
AAR CORP. has filed a formal investor education presentation to be used in meetings with existing and prospective investors. The presentation provides a strategic overview of the company's operations and includes updates regarding its pending acquisition of MRO Holdings, Inc.
Axcelis Technologies appointed Jeroen Delsman as Executive Vice President and Chief Financial Officer, effective November 12, 2026. His compensation package includes a $500,000 base salary, a $352,000 sign-on bonus, and a $1.2 million sign-on RSU award, plus eligibility for future annual equity awards and a performance-based special equity grant tied to the pending Veeco merger.
Hubbell reported strong third quarter 2026 results with net sales increasing 25% to $1.87 billion, driven by 11% organic growth and 13% from M&A. The company saw significant strength in its Electrical Solutions segment, particularly in data center markets, leading management to raise its full-year 2026 adjusted EPS guidance.
Term
Q3 2026
“Hubbell delivered strong financial performance in the third quarter, with double digit growth in organic sales, adjusted operating profit, adjusted earnings per share and free cash flow”
Gerben Bakker, Chairman, President and CEO
“Third quarter results were highlighted by >20% organic growth in Electrical Solutions, led by strong datacenter markets and bolstered by content gains and capacity expansion investments.”
PACCAR reported record third quarter 2026 revenues of $7.94 billion and net income of $847.5 million, representing a 44% increase in profit year-over-year. The results were driven by higher truck segment margins and record performance in the PACCAR Parts division, which achieved $1.78 billion in quarterly revenue.
Term
Q3 2026
“PACCAR achieved excellent results in the third quarter of 2026. Revenues increased by 19% and net income increased by 44% compared to same period last year. The increase in quarterly profits resulted from higher truck segment margins and strong overall business performance. PACCAR Parts reported record revenues and PACCAR Financial Services achieved very good profits. I am very proud of our employees who design, build, and deliver the company’s trucks and transportation solutions to our customers.”
Preston Feight, chief executive officer
“Kenworth and Peterbilt’s customers are beginning to refresh their fleets with newer, more fuel efficient trucks. We are experiencing a good year of truck demand in 2026 and we anticipate this to continue next year, supported by U.S. economic growth and continued investments in infrastructure.”
John Rich, PACCAR executive vice president and chief technology officer
60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.
Camden National Corporation reported Q3 2026 net income of $22.8 million and diluted EPS of $1.34, representing an 8% increase in net income year-over-year. The results were driven by 5% deposit growth and a 15 basis point expansion of the net interest margin to 3.41%.
Term
Q3 2026
“Our third-quarter results demonstrate continued momentum across the franchise, with year-over-year earnings growth, meaningful deposit growth, and strong credit performance.”
Simon Griffiths, President and Chief Executive Officer
“With record earnings through the first nine months of the year and a stronger balance sheet, we are confident that we are well positioned to deliver sustained earnings growth and long-term shareholder value.”
Simon Griffiths, President and Chief Executive Officer
Ecolab reported third quarter 2026 results featuring 13% reported sales growth and a 5% increase in adjusted diluted EPS to $2.18. The company highlighted strong organic sales growth of 63% in its Global High-Tech segment and 17% in Life Sciences, driven by the performance of recent acquisitions Ovivo Electronics and CoolIT.
Term
Q3 2026
“Third quarter results marked an inflection point in Ecolab's performance. Exceptional execution drove accelerating sales growth, margin expansion and double-digit adjusted operating income growth. Volume growth accelerated to 2% despite ongoing disruptions in the Middle East. As expected, pricing strengthened to 5% as we leveraged total value delivered to mitigate higher commodity costs while improving customer performance. This disciplined execution allowed us to stabilize our organic gross margin.”
Christophe Beck, Ecolab’s chairman, president and chief executive officer
Obook Holdings CEO Chun Kai Wang Buys $22.3K of Stock
Chun Kai Wang, CEO, bought 11,105 shares of Obook Holdings Inc. at $2.01 a share, worth $22.3K in total on Oct 26, 2026. Shares held after the trade: 3,148,105 (+0.4%).
CTS Corporation reported third-quarter 2026 sales of $149.6 million, a 5% increase year-over-year driven by strength in diversified end-markets. The company achieved record margins and raised its full-year 2026 guidance for both sales and adjusted EPS, citing disciplined execution and the strategic acquisition of Millar.
Term
Q3 2026
“CTS delivered another strong quarter, with sales increasing 5% year over year, driven by continued strength across our increasingly diversified portfolio. Diversified end-market sales grew 7% and now represent 60% of total sales, while Transportation sales also posted modest growth.”
Pratik Trivedi, CEO of CTS Corporation
“Our disciplined execution is delivering profitable growth, record margins and strong cash generation. The acquisition of Millar further advances our diversification strategy, especially in the medical end market, and enhances our opportunity to create sustainable long-term value.”
Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira, currently the CMO of Organon & Co., as a Class II director effective December 1, 2026. Simultaneously, Haya Taitel notified the board of her resignation as a director, also effective December 1, 2026. Dr. Arjona Ferreira will participate in the company's standard non-employee director compensation program.
Smithfield Foods reported third quarter 2026 sales of $3.4 billion, an 8.3% decrease year-over-year, driven by pressure in upstream pork commodity markets. Despite the decline, the Packaged Meats segment delivered higher operating profit and the company completed its acquisition of Nathan’s Famous to bolster its brand portfolio.
Term
Q3 2026
“We reported third quarter adjusted operating profit within the range we provided in September, led by strong results in our cornerstone Packaged Meats segment, with our upstream segments challenged by lower pork commodity markets.”
Shane Smith, President and CEO
“Packaged Meats remains on track to deliver its fifth consecutive year above $1 billion in operating profit in fiscal 2026. The completion of the Nathan’s Famous acquisition further strengthens our brand portfolio and expands our opportunities for profitable growth.”
Central Bancompany reported Q3 2026 net income of $116.2 million, or $0.48 per diluted share, driven by net interest margin expansion to 4.48%. The company saw average total deposits grow 4.4% year-over-year to $15.4 billion, while maintaining strong asset quality with nonperforming assets at just 33 basis points of total assets.
Term
3 years
“We delivered another strong quarter, supported by continued balance sheet growth, disciplined expense management, and solid credit quality. Adjusted net income increased $13.7 million from a year ago and $2.8 million from the prior quarter.”
John “JR” Ross, President and Chief Executive Officer
“Underlying business fundamentals remained healthy across our franchise. Average total deposits increased more than 4% from the prior-year quarter, including 6% growth in noninterest-bearing deposits, while average loans grew at an annualized rate of more than 3% from the prior quarter despite our continued focus on reducing certain consumer loan balances.”
John “JR” Ross, President and Chief Executive Officer
Skyline Bankshares reported record third-quarter net income of $5.1 million, or $0.90 per share, driven by organic loan growth and an expanded net interest margin of 4.61%. Total assets grew to $1.35 billion, supported by a 6.92% increase in net loans since the end of 2025. The company also expanded its footprint with the opening of a new branch in Dobson, North Carolina.
Term
Q3 2026
“We are pleased to report another quarter of record earnings for Skyline while continuing to invest in future growth, including the September opening of our newest branch in Dobson, North Carolina.”
Blake Edwards, President and CEO
“We believe we remain well positioned for continued growth and success in the future and look forward to the opportunities ahead for the Skyline family.”
Wave Life Sciences reported total assets of $507.9 million as of September 30, 2026, a decrease from $638.5 million at year-end 2025, primarily driven by a reduction in cash and cash equivalents. The company transitioned a significant portion of its liquidity into marketable securities and reported 197,228,968 shares of common stock outstanding as of October 21, 2026.
Terrestrial Energy's Board of Directors has authorized a share repurchase program to buy back up to $25 million of its common stock. The program will be funded from existing cash on hand and is scheduled to expire on October 22, 2027. Management will determine the timing and volume of repurchases based on market conditions and capital requirements.
Commvault Systems reported Q2 fiscal 2027 results with subscription revenue growing 21% year-over-year to $269 million and subscription ARR reaching $1.1 billion. The company raised its full-year fiscal 2027 guidance for subscription revenue and ARR, citing strong momentum in enterprise cyber resilience and AI-driven demand.
Term
Q2 2027
“With AI accelerating both innovation and risk in the enterprise, resilience continues to be a business imperative. Enterprises globally are increasingly turning to Commvault to stay resilient as they navigate more data, more identities, and greater complexity. We believe our strong Q2 results reflect that momentum, driving durable growth and shareholder value.”
Norwood Financial Corp reported record Q3 2026 net income of $11.8 million and record net interest income of $28.0 million. Results were driven by disciplined execution and contributions from the Presence Bank acquisition, alongside a net interest margin expansion to 4.01%.
Term
Q3 2026
“The entire Wayne Bank team continued to perform well in the third quarter, delivering record net income and net interest income for the second consecutive quarter. In addition to strong income growth, we navigated the bankruptcy related to a borrower relationship, resolving the issue with favorable outcome.”
Jim Donnelly, President and Chief Executive Officer
Zura Bio reported third quarter 2026 financial results, highlighting a cash position of $187.7 million which is expected to fund operations through 2028. The company remains on track for topline Phase 2 data readouts for tibulizumab in hidradenitis suppurativa (Q4 2026) and systemic sclerosis (H1 2027).
“Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer
“We continue to believe deeply in tibulizumab’s potential to address complex immune biology and unmet needs across indications, including in PMR, where we will be starting the NEXUS-PMR study by end of year. With cash runway sufficient to deliver results from all three studies, Zura is in a great position to deliver on tibulizumab’s unique potential.”
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer